Stereotaxis $24M Debt Financing with certain accredited investors
Stereotaxis entered into a Note Purchase Agreement to issue up to $24.0 million in convertible promissory notes, with an initial $12.0 million closing on November 9, 2026. The notes bear 10% interest, mature in three years, and are convertible into common stock at an initial price of $1.21 per share.
- Value
- $24M
- Counterparty
- certain accredited investors
- Term
- 3 years
“Our near-term priority is to drive forward two major business model transformations. The first is shifting from capital systems that require long sales and construction timelines, to having a portfolio of systems that are significantly more accessible and scalable. The second is developing and commercializing a portfolio of disposable interventional catheters that enhance the value of our robots and provide a robust recurring revenue opportunity.”
David Fischel, Chairman and CEO
“System revenue of $3 million in the quarter was up 60% compared to last year, benefiting from partial revenue recognition from the first GenesisX system in the US, the first Genesis system in China, and multiple Synchrony digital operating room systems in the US.”
David Fischel, Chairman and CEO